Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Relx PLC Director's Dealing 2020

Jul 24, 2020

5248_dirs_2020-07-24_63cab5c4-f14c-400b-8b54-2efef6590ddb.html

Director's Dealing

Open in viewer

Opens in your device viewer

{# SEO P0-1: filing HTML is rendered server-side so Googlebot sees the full text without executing JS or following an iframe to a Disallow'd CDN path. The content has already been sanitized through filings.seo.sanitize_filing_html. #}

National Storage Mechanism | Additional information

RNS Number : 0627U

RELX PLC

24 July 2020

ISSUED ON BEHALF OF RELX PLC

Director/PDMR Shareholding

1 Details of the person discharging managerial responsibilities / person closely associated
a) Name Henry Udow
2 Reason for the notification
a) Position/status PDMR
b) Initial notification /Amendment Initial Notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name RELX PLC
b) LEI 549300WSX3VBUFFJOO66
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares of 14 51/116p each ('Ordinary Shares')
Identification code ISIN: GB00B2B0DG97
b) Nature of the transaction Exercise of options over 719 Ordinary Shares, granted 26 April 2017 under the RELX Group plc 2013 SAYE Share Option Scheme
c) Price(s) and volume(s)
Price(s) Volume(s)
£12.512 719
d) Aggregated information
- Aggregated volume 719
- Price £12.512
e) Date of the transaction 2020-07-23
f) Place of the transaction Outside of a trading venue

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

DSHFLFVVDDISFII